// App-Quantinova.ai

BSH2020‐PO‐007 : Targeting SET‐PP2A complex as a new avenue of treatment for Mixed Lineage Leukemia (MLL) treatment

Researchers

Presenter

  • A. Di Mambro

Principal Investigators

  • Y. Arroyo-Berdugo

  • Y. Calle

  • B. Wrench

  • J. Gribben

  • M. T. Esposito

Medical Centers

  • Life Sciences, University of Roehampton

  • Hemato‐Oncology, Queen Mary University of London, London, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Nucleoside diphosphate kinase A

  • Protein Phosphatase 2 Phosphatase Activator

  • Extracellular signal-regulated kinase

  • Histone-lysine N-methyltransferase 2A

  • L-serine

Drug/Treatment

  • FTY720

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved